ICML 2023 | Selecting BTK inhibitors for patients with MCL
Preetesh Jain, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on factors to consider when selecting Bruton’s tyrosine kinase inhibitors (BTKi) for patients with mantle cell lymphoma (MCL). Dr Jain comments on the safety profile of ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib, and stresses the importance of cardiovascular assessment in patients being treated with BTKi. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: Kite, Eli Lilly, Loxo oncology
Honoraria: Aptitude health, pharmacy times
Research funding: Astra Zeneca, Kite, beigene
Educational grants: Dava oncology
